梅奥诊所选定下一任首席执行官：Callstrom 2027年1月接替 Farrugia
梅奥诊所（Mayo Clinic）董事会11月13日在明尼苏达州 Rochester 宣布，选定 Matthew R. Callstrom 医学博士为该机构下一任总裁兼首席执行官，接替 Gianrico Farrugia 医学博士。Farrugia 将任职至2026年12月31日，期间与 Callstrom 共同完成交接，Callstrom 于2027年1月1日正式上任。
Callstrom 于2002年加入梅奥诊所，在该机构工作近25年，现为梅奥诊所理事会与董事会成员，并担任梅奥诊所战略部门与生成式超级智能（SI）项目的医学主任。他此前曾任临时首席战略官，以及梅奥诊所 Rochester 放射科主任。
Callstrom 是一名医生科学家和体部介入放射科医生，在影像引导癌症治疗领域享有国际声誉，曾参与开发更精准识别与治疗癌症的技术，主持和参与多项临床试验，发表论文与获得专利合计200多项。他曾获梅奥诊所杰出临床医生称号，并曾担任介入肿瘤学会主席。
Callstrom 是明尼苏达州本地人，先后取得明尼苏达大学双城分校化学工程与化学学位，在哈佛大学完成博士后研究，随后在梅奥诊所 Alix 医学院取得医学学位，并在 Rochester 完成放射诊断住院医师与横断面影像专科培训。
梅奥诊所董事会主席 Richard K. Davis 表示，Callstrom 在临床、科研、战略与创新方面经验丰富，善于把科学发现与新兴技术转化为对患者有实际意义的进展。Callstrom 表示，自己深感荣幸能领导梅奥诊所，机构将加快把研究发现与新兴技术转化为更好的诊疗，并把服务延伸到更多地方的患者。
Farrugia 自2019年起担任梅奥诊所总裁兼首席执行官，任内推出并推进「Bold. Forward.」战略，并建成梅奥诊所首个可规模化、由超级智能（SI）支持的诊疗转型平台 Mayo Clinic Platform。他表示，Callstrom 深知梅奥诊所、也清楚医疗的发展方向，有信心把机构带入下一阶段。
梅奥诊所是一家非盈利机构，总部位于明尼苏达州 Rochester，以临床实践、教育与科研创新著称，为有需要的患者提供诊疗服务。（来源：梅奥诊所）
Mayo Clinic Elects Matthew R. Callstrom as Next President and CEO, Succeeding Gianrico Farrugia on January 1, 2027
The Mayo Clinic Board of Trustees announced in Rochester, Minnesota, on November 13 that it has elected Matthew R. Callstrom, M.D., Ph.D., as the organization's next president and chief executive officer, succeeding Gianrico Farrugia, M.D. Farrugia will remain president and CEO through December 31, 2026, working closely with Callstrom on the transition, and Callstrom will assume the position on January 1, 2027.
Callstrom joined Mayo Clinic in 2002 and has spent nearly 25 years at the organization. A member of Mayo Clinic's Board of Governors and Board of Trustees, he serves as medical director for Mayo Clinic Strategy and the Generative Super Intelligence (SI) Program, and previously served as interim chief strategy officer and chair of the Department of Radiology at Mayo Clinic in Rochester.
A physician-scientist and body interventional radiologist, Callstrom is internationally recognized for advancing image-guided cancer treatment, including technologies that more precisely identify and treat cancer. He has led and collaborated on numerous clinical trials, and his work has resulted in more than 200 publications and patents. He has been recognized as a Mayo Clinic Distinguished Clinician and served as president of the Society of Interventional Oncology.
A Minnesota native, Callstrom earned degrees in chemical engineering and chemistry from the University of Minnesota Twin Cities and completed a postdoctoral fellowship at Harvard University before earning his medical degree from Mayo Clinic Alix School of Medicine. He completed his residency in diagnostic radiology and a fellowship in cross-sectional imaging at Mayo Clinic in Rochester.
Richard K. Davis, chair of the Mayo Clinic Board of Trustees, said Callstrom brings nearly 25 years of experience at Mayo Clinic across patient care, research, strategy and innovation, and an ability to translate scientific discovery and emerging technology into meaningful advances for patients. Callstrom said he was deeply honored to lead Mayo Clinic and that the organization would accelerate the translation of discovery and emerging technologies into better care for more patients, wherever they are.
Farrugia has served as president and CEO since 2019. Under his leadership, Mayo Clinic launched and advanced Bold. Forward., its strategy to transform healthcare, and created Mayo Clinic Platform, its first comprehensive, scalable, SI-enabled care transformation platform. He said Callstrom knows Mayo Clinic deeply and understands where healthcare is headed.
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, headquartered in Rochester, Minnesota. (Source: Mayo Clinic)
来源：梅奥诊所
发布：GSM·美国（发布链接）
图片来源：图：梅奥诊所 Plummer 大楼，位于明尼苏达州 Rochester，是梅奥诊所的标志性建筑。w_lemay 摄，CC BY-SA 2.0 授权，经 Wikimedia Commons。 / Photo: The Plummer Building, the landmark building of Mayo Clinic in Rochester, Minnesota. Photo by w_lemay, CC BY-SA 2.0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
